Side Effects and Metabolic Effects of Converting-Enzyme Inhibitors

References

• Baker K. M., Johns D. W., Ayers C. R., Carey R. M. Ischemic cardiovascular complications concurrent with administration of captopril. Hypertension 1980; 2: 73–74
   PubMed Web of Science ®Google Scholar
• Hodsman G. P., Isles C. G., Murray G. D., Usherwood T. P., Webb D. J., Robertson J. I. S. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J 1983; 286: 832–834
   PubMed Web of Science ®Google Scholar
• Barraclough M. A. Sodium and water depletion with acute malignant hypertension. Am J Med 1966; 40: 265–272
   PubMed Web of Science ®Google Scholar
• McAreavey D., Brown J. J., Cumming A. M. M., Davies D. L., Fraser R., Lever A. F., Mackay A., Morton J. J., Robertson J. I. S. Inverse relation of exchangeable sodium and blood pressure in hypertensive patients with renal artery stenosis. J Hypertension 1983; 1: 297–302
   PubMedGoogle Scholar
• Atkinson A. B., Brown J. J., Davies D. L., Fraser R., Leckie B., Lever A. F., Morton J. J., Robertson J. I. S. Hyponatraemic hypertensive syndrome with renal-artery occlusion corrected by captopril. Lancet 1979; i: 606–609
   Google Scholar
• Heslop H., Richards A. M., Nicholls M. G., Espiner E. A., Ikram H., Maslowski A. H. Hyponatraemic-hypertensive syndrome due to unilateral renal ischaemia in women who smoke heavily. NZ Med J 1985; 98: 739–742
   PubMedGoogle Scholar
• Cleland J. G. F., Dargie H. J., McAlpine H., Ball S. G., Morton J. J., Robertson J. I. S., Ford I. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1985; 291: 1309–1312
   PubMed Web of Science ®Google Scholar
• Warren S. E., O'Connor D. T. Hyperkalemia resulting from captopril administration. JAMA 1980; 244: 2551–2552
   PubMed Web of Science ®Google Scholar
• Textor S. C., Bravo E. L., Fouad F. M., Tarazi R. C. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73: 719–725
   PubMed Web of Science ®Google Scholar
• Burnakis T. G., Mioduch H. J. Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia. Arch Intern Med 1984; 144: 2371–2372
   PubMed Web of Science ®Google Scholar
• Zanella M. T., Mattei E., Jnr, Draibe S. A., Kater C. E., Ajzen H. Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure. Clin Pharmacol Ther 1985; 38: 613–617
   PubMed Web of Science ®Google Scholar
• Cox M., Sterns R. H., Singer I. The defense against hyperkalemia: the roles of insulin and aldosterone. N Eng J Med 1978; 299: 525–532
   PubMed Web of Science ®Google Scholar
• Popp D., Achtenberg J. F., Cryer P. E. Hyperkalemia and hyperglycemic increments in plasma potassium in diabetes mellitus. Arch Intern Med 1980; 140: 1617–1621
   PubMed Web of Science ®Google Scholar
• Clive D. M., Stoff J. S. Renal syndromes associated with nonsteroidal anti inflammatory drugs. N Eng J Med 1984; 310: 563–572
   PubMed Web of Science ®Google Scholar
• Tan S. Y., Shapiro R., Franco R., Stockard H., Mulrow P. J. Indomethacin-induced prostaglandin inhibition with hyperkalemia: a reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med 1979; 90: 783–785
   PubMed Web of Science ®Google Scholar
• Ponce S. P., Jennings A. E., Madias N. E., Harrington J. T. Drug-induced hyperkalemia. Medicine 1985; 64: 357–370
   PubMed Web of Science ®Google Scholar
• Hricik D. E., Browning P. J., Kopelman R., Goorno W. E., Madias N. E., Dzau V. J. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. N Eng J Med 1983; 308: 373–376
   PubMed Web of Science ®Google Scholar
• Crozier I. G., Ikram H., Nicholls M. G., Jans S. Acute hemodynamic, hormone, and electrolyte effects of ramipril in severe congestive heart failure. Am J Cardiol, (In Press)
   Web of Science ®Google Scholar
• Boner G., Morduchowicz G., Rotenberg Z., Weinberger I., Shohat J., Rosenfeld J. B. Deterioration in renal function in patients with chronic renal failure after treatment with captopril. Israel J Med Sci 1985; 21: 892–894
   PubMedGoogle Scholar
• Murphy B. F., Whitworth J. A., Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J 1984; 288: 844–845
   PubMed Web of Science ®Google Scholar
• Cleland J. G. F., Dargie H. J., Ball S. G., Gillen G., Hodsman G. P., Morton J. J., East B. W., Robertson I., Ford I., Robertson J. I. S. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985; 54: 305–312
   PubMedGoogle Scholar
• Hollenberg N. K., Swartz S. L., Passan D. R., Williams G. H. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. N Eng J Med 1979; 301: 9–12
   PubMed Web of Science ®Google Scholar
• Gluck Z., Beretta-Piccoli C., Reubi F. C. Long-term effects of captopril on renal function in hypertensive patients. Eur J Clin Pharmacol 1984; 26: 315–323
   PubMed Web of Science ®Google Scholar
• Herlitz H., Edeno C., Mulec H., Westberg G., Aurell M. Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron 1984; 38: 253–256
   PubMed Web of Science ®Google Scholar
• Mujais S. K., Fouad F. M., Textor S. C., Tarazi R. C., Bravo E. L., Hart N., Gifford R. W., Jnr. Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J 1984; 52: 63–71
   PubMedGoogle Scholar
• Bauer J. H., Reams G. P. Hemodynamic and renal function in essential hypertension during treatment with enalapril. Am J Med 1985; 79(Suppl 3C)10–13
   PubMed Web of Science ®Google Scholar
• Jenkins A. C., Dreslinski G. R., Tadros S. S., Groel J. T., Fand R., Herczeg S. A. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol 1985; 7(Suppl 1)S96–S101
   PubMed Web of Science ®Google Scholar
• McMurray J., Matthews D. M. Effect of diarrhoea on a patient taking captopril. Lancet 1985; i: 581
   Google Scholar
• Benett P. R., Cairns S. A. Captopril, diarrhoea, and hypotension. Lancet 1985; 1: 1105
   PubMed Web of Science ®Google Scholar
• Coulshed D. J., Davies S. J., Turney J. H. Prolonged hypotension after fever during enalapril treatment. Lancet 1985; ii: 222
   Google Scholar
• Davies R. O., Irvin J. D., Kramsch D. K., Walker J. F., Moncloa F. Enalapril worldwide experience. Am J Med 1984; 77(2A)23–35
   PubMed Web of Science ®Google Scholar
• Moncloa F., Sromovsky J. A., Walker J. F., Davies R. O. Enalapril in hypertension and congestive heart failure. Drugs 1985; 30(Suppl 1)82–89
   PubMedGoogle Scholar
• Helgeland A., Strommen R., Hagelund C. H., Tretli S. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. Lancet 1986; i: 872–875
   Google Scholar
• Keith I. M., Will J. A., Weir E. K. Captopril: association with fetal death and pulmonary vascular changes in the rabbit (41446). Proc Soc Exp Biol Med 1982; 170: 378–383
   PubMed Web of Science ®Google Scholar
• Broughton Pipkin F., Turner S. R., Symonds E. M. Possible risk with captopril in pregnancy: some animal data. Lancet 1980; i: 1256
   Google Scholar
• Norman J. A., Autry W. L., Barbaz B. S. Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [met]-enkephalin-arg6-phe7 by inhibiting its degradation in mouse brain. Mol Pharmacol 1985; 28: 521–526
   PubMed Web of Science ®Google Scholar
• Callender J. S., Hodsman G. P., Hutcheson M. J., Lever A. F., Robertson J. I. S. Mood changes during captopril therapy for hypertension: a double-blind pilot study. Hypertension 1983; 5(Suppl III)111–90, 111-93
   Google Scholar
• Velletri P. A. Testicular angiotensin I-converting enzyme (E.C. 3.4.15.1). Life Sci 1985; 36: 1597–1608
   PubMed Web of Science ®Google Scholar
• Ferriere M., Lachkar H., Richard J-L., Bringer J., Orsetti A., Mirouze J. Captopril and insulin sensitivity. Ann Intern Med 1985; 102: 134–135
   PubMed Web of Science ®Google Scholar
• Weinberger M. H. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5(Suppl III)IIII-132–III-138
   Google Scholar
• Malini P. L., Strocchi E., Ambrosioni E., Magnani B. Long-term antihypertensive, metabolic and cellular effects of enalapril. J Hypertension 1984; 2(Suppl 2)101–105
   Google Scholar
• Gambaro G., Morbiato F., Cicerello E., Del Turco M., Sartori L., D'Angelo A., Crepaldi G. Captopril in the treatment of hypertension in type I and type II diabetic patients. J Hypertension 1985; 3(Suppl 2)S149–S151
   PubMedGoogle Scholar
• Sullivan P. A., Kelleher M., Twomey M., Dineen M. Effects of converting enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma aldosterone in hypertensive diabetics compared to patients with essential hypertension. J Hypertension 1985; 3: 359–363
   PubMed Web of Science ®Google Scholar
• Leary W. P., Reyes A. J., Acosta-Barrios T. N., Maharaj B. Captopril once daily as monotherapy in patients with hyperuricemia and essential hypertension. Lancet 1985; i: 1277
   Google Scholar
• McNabb W. R., Noormohamed F. H., Brooks B. A., Till A. E., Lant A. F. Effects of repeated doses of enalapril on renal function in man. Br J Clin Pharmac 1985; 19: 353–361
   PubMed Web of Science ®Google Scholar
• Navis G. J., De Jong P. E., De Zeeuw D. Serum uric acid, ACE inhibitors, and natriuresis. Lancet 1985; ii: 156
   Google Scholar
• Hill J. F., Bulpitt C. J., Fletcher A. E. Angiotensin converting enzyme inhibitors and quality of life: the European trial. J Hypertension 1985; 3(Suppl 2)S91–S94
   Google Scholar